Auriga Medical is the new name for the medical therapeutics business of QSA Global. The QSA Global group of businesses
has a proud heritage spanning over 100 years in the design, manufacture, and delivery of quality radioisotope products for medicine, research, and
industry. With the launch of Auriga Medical, we are focusing our technical, financial, and human resources on the growing needs for specialized
radioactive products in the treatment of cancer and other diseases.
|
1901
|
- First industrial production of the naturally-radioactive element radium at Buchler & Company factory in Braunschweig, Germany.
|
|
1940
|
- Patrick Grove begins the refining of radium at Chilcote house in Amersham, England.
|
|
1940s
|
- Emphasis on radium business in UK and Germany changes from luminous paints for compasses, gunsights and aircraft instruments to medical products for cancer treatment. Radiochemical Center is formed within the UK government.
|
|
Early 1950s
|
- Expansion at the Amersham site - new manufacturing processes include man-made isotopes and advanced technologies for metal encapsulation.
|
|
1954
|
- The Radiochemical Center becomes part of the United Kingdom Atomic Energy Authority at Amersham and Harwell, England.
|
|
1956
|
- Buchler site becomes the first privately operated radioisotope laboratory in Germany.
|
|
1958
|
- Distribution agreement for radioactive products between Radiochemical Center in the U.K. and Buchler & Company in Germany.
|
|
1968
|
- Partnership formed between Amersham and G D Searle in the U.S. to form Amersham/Searle.
|
|
1971
|
- Radiochemical Center becomes a private company and establishes Amersham Buchler subsidiary in Braunschweig, Germany.
|
|
1977 & 1978
|
- Wholly - owned subsidiaries established in the U.S., Australia, France, and the Netherlands.
|
|
1978
|
- First company to use laser welding to produce sealed radioactive sources for medical and industrial applications.
|
|
1981
|
- Company renamed Amersham International plc
|
|
1987
|
- AEA Technology plc. begins production of Yttrium-90 for clinical use, and provides this product to developers of radioimmunotherapy agents in the UK and Europe.
|
|
1998
|
- QSA divested by Amersham and acquired by AEA Technology plc, headquartered at Harwell.
|
|
2001
|
- QSA began the production of Strontium-90 sources for use in clinical trials for the Novoste 3.5F Beta Cath product for the treatment of in-stent restenosis following angioplasty.
|
|
January 2003
|
- First use of Auriga Medical brand at Society of Nuclear Medicine Mid-Winter Symposium in Fort Lauderdale, FL.
|
|
October 2005
|
- QSA divested by AEA Technology plc and acquired by Coller Capital, the leading global investor in private equity secondaries. Auriga Medical is now a brand of QSA Global.
|
